Wells Fargo & Company Adial Pharmaceuticals, Inc. Call Options Transaction History

Wells Fargo & Company

  • $434 Billion
  • Q3 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

Others Institutions Holding ADIL

# of Institutions
1
Shares Held
5.5K
Call Options Held
0
Put Options Held
0
View Full List

About ADIAL PHARMACEUTICALS, INC.

ADIL Quotes by TradingView
  • Ticker ADIL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,854,000
  • Market Cap $26.9M
  • Description
  • Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focu...
More about ADIL
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email